Clinical Trial Update: A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) [Phase 3]

View source ↗

Summary

Phase 3 pivotal trial comparing VB-111 plus bevacizumab versus bevacizumab in recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• VB-111

Snippet

Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics | Conditions: Glioblastoma | Phase 3 | Status: COMPLETED